DUROLANE

Resident Time in Joint

  • DUROLANE was shown to have a half-life of 4 weeks or 32 days in the joint following a single injection.3,6
  • DUROLANE has a longer half-life than cross-linked and unstabilized hylan G-F 20 (Synvisc® and Synvisc-One®).4,5

Resident Time in Joint

Graphs based on elimination of hyaluronic acid (HA) from the joint space of rabbits as a function of time for DUROLANE6 as compared against extrapolated data for the residence time of hylan G-F 204 and low molecular weight HA5 in a similar rabbit model. DUROLANE values calculated based on projected clearance of one-3 mL injection (20 mg/mL). Hylan G-F 20 values calculated based on projected clearance of one-6 mL injection (representing Synvisc-One®) or three-2.0 mL injections (representing Synvisc-3 injection regimen) of HA at 16 mg/mL in a rabbit model.4 As shown in the graph, DUROLANE human data correlates well with the rabbit model.3

Bioventus

Summary of Indications for Use
DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.
Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in Product Labeling.

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2017 Bioventus LLC.

Durolane-since-2001
*First introduced in the European Union in 2001.

To learn more about DUROLANE or for contact information, please select your location to continue.

Osteoarthritis: The Ongoing Challenges to Manage Pain

https://player.vimeo.com/video/125047428

Osteoarthritis: The Ongoing Challenges to Manage Pain